Vivos therapeutics reports first quarter 2024 financial results and provides operational update

Vivos expanding its revenue generating initiatives as operating expenses decrease 22%, representing seven consecutive quarters of year over year improvement due to successful cost cutting initiatives

VVOS Ratings Summary

VVOS Quant Ranking